Literature DB >> 19330868

Antiangiogenic therapy: not just for cancer anymore?

Vijay H Shah, Jordi Bruix.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19330868     DOI： 10.1002/hep.22872

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  10 in total

Review 1.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

2.  Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.

Authors:  Enis Kostallari; Petra Hirsova; Alena Prasnicka; Vikas K Verma; Usman Yaqoob; Nicha Wongjarupong; Lewis R Roberts; Vijay H Shah
Journal:  Hepatology       Date:  2018-05-10       Impact factor: 17.425

3.  Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases.

Authors:  Claudia Paternostro; Ezio David; Erica Novo; Maurizio Parola
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

4.  Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway.

Authors:  Qian Ding; Xiang-Guo Tian; Yan Li; Qi-Zhi Wang; Chun-Qing Zhang
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

5.  Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

Authors:  Romain Coriat; Hervé Gouya; Olivier Mir; Stanislas Ropert; Olivier Vignaux; Stanislas Chaussade; Philippe Sogni; Stanislas Pol; Benoit Blanchet; Paul Legmann; François Goldwasser
Journal:  PLoS One       Date:  2011-02-14       Impact factor: 3.240

6.  Ultrasound molecular imaging with cRGD-PLGA-PFOB nanoparticles for liver fibrosis staging in a rat model.

Authors:  Jiqing Xuan; Yuli Chen; Leilei Zhu; Yuan Guo; Liming Deng; Yuanyi Zheng; Zhaoxia Wang; Zhigang Wang; Meng Ao
Journal:  Oncotarget       Date:  2017-09-28

Review 7.  Angiogenesis and Fibrogenesis in Chronic Liver Diseases.

Authors:  Claudia Bocca; Erica Novo; Antonella Miglietta; Maurizio Parola
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-07-13

8.  Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension.

Authors:  Javier Gallego; Ester Garcia-Pras; Marc Mejias; Nuria Pell; Ute Schaeper; Mercedes Fernandez
Journal:  Sci Rep       Date:  2017-11-01       Impact factor: 4.379

9.  The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension.

Authors:  Tom Luedde; Jonel Trebicka; Frank Erhard Uschner; Florian Schueller; Ivelina Nikolova; Sabine Klein; Robert Schierwagen; Fernando Magdaleno; Stefanie Gröschl; Sven Loosen; Thomas Ritz; Christoph Roderburg; Michael Vucur; Glen Kristiansen; Twan Lammers
Journal:  Oncotarget       Date:  2018-11-16

10.  XSSJS inhibits hepatic fibrosis by promoting the miR-29b-3p/VEGFA axis in vitro and in vivo.

Authors:  Tianyao Zhang; Yu Yang; Baojia Wang; Long Wang; Dong Wang; Ning Cao; Jinyu Shi
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.